New drug shows promise for rare kidney disease

NCT ID NCT06513338

Completed Disease control Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tested a drug called eculizumab in 16 people with anti-GBM disease, a severe autoimmune condition that often leads to kidney failure. The drug blocks a part of the immune system believed to cause kidney damage. Researchers measured how many patients avoided dialysis or kidney transplant, and tracked kidney function changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Eculizumab (a drug that blocks a part of the immune system called complement C5)
What this could lead to: If it works, this could offer a new treatment option for anti-GBM disease, potentially reducing the need for dialysis or kidney transplant.
What could go wrong: This is a small, early-phase trial with only 16 people, so results may not apply to everyone. The drug also increases risk of serious infections like meningitis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-glomerular basement membrane disease autoimmune disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES

Contacts and locations

Locations

Peking University First Hospital

Beijing, 100038, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.